Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2024-10-09 DOI:10.1016/j.ygyno.2024.07.024

Panagiotis Konstantinopoulos , Jae-Weon Kim , Gilles Freyer , Jung-Yun Lee , Lydia Gaba , Rachel Grisham , Nicoletta Colombo , Xiaohua Wu , Jalid Sehouli , Felipe Cruz , David Cibula , Bradley Monk , Gitte-Bettina Nyvang , Michael Friedlander , Domenica Lorusso , Els Van Nieuwenhuysen , Rosalind Glasspool , Christian Marth , Patsy Hinson , Monica Zuradelli , Antonio González-Martín

引用次数: 0

查看原文本刊更多论文

在无 BRCA 基因突变的铂类耐药或难治性高级别浆液性卵巢癌患者中，阿来替尼联合奥拉帕利与化疗相比的疗效和安全性：EPIK-O 试验的初步分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy